NYSE · Biotechnology

ADC Therapeutics SA (ADCT) Stock

$1.73 +8.81% NYSE: ADCT Healthcare

Valuation

MetricValue
Price$1.73
Market Cap$220.04M
P/E Ratio-2.14
P/B Ratio-0.96
P/S Ratio2.29
EPS (TTM)$-1.12
52-Week High$4.98
52-Week Low$0.78
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE44.63%
ROA-34.69%
ROCE-51.34%
Gross Margin-134.57%
Operating Margin-133.33%
Net Margin-123.03%
Debt/Equity-1.83
Current Ratio4.37

Annual Financials (USD)

Metric20212022202320242025
Revenue$34.0M$210.0M$70.0M$71.0M$81.0M
Operating Profit$-262.0M$-123.0M$-166.0M$-131.0M$-108.0M
Net Profit$-230.0M$-157.0M$-240.0M$-158.0M$-143.0M
EPS$-3.00$-1.99$-2.94$-1.62$-1.12
Op Margin-771.6%-58.8%-238.6%-184.4%-133.2%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$618.0M$491.0M$355.0M$322.0M$323.0M
Total Liabilities$452.0M$411.0M$503.0M$525.0M$509.0M
Cash$467.0M$326.0M$279.0M$251.0M$261.0M
Borrowings$140.0M$130.0M$124.0M$123.0M$439.0M

Latest News

The Cancer Therapy Strategy VERAXA Is Betting the Company On Exec Edge · Jul 6, 2026 ADC Therapeutics Announces New Employee Inducement Grant PR Newswire · Jul 1, 2026 ADC Therapeutics Completes Enrollment in LOTIS-7 Lymphoma Study MT Newswires · Jun 30, 2026 ADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA® Combination Trial PR Newswire · Jun 30, 2026 ADC Therapeutics (ADCT) Stock Fair Value Falls After LOTIS 5 Reshapes Analyst Views Simply Wall St. · Jun 27, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-233.0M$-137.0M$-119.0M$-124.0M$-141.0M
Investing Cash Flow$-13.0M$-3.0M$-6.0M$-2.0M$0
Financing Cash Flow$219.0M$-120.0M$74.0M$37.0M$-2.0M
Net Cash Flow$27.0M$-140.0M$-48.0M$-28.0M$10.0M
Free Cash Flow$-240.0M$-137.0M$-122.0M$-125.0M$-141.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.02
EV / EBITDA-4.32
FCF Yield-56.65%
Quick Ratio2.97
Interest Coverage-1.90
Return 1Y-63.28%
Return 3Y-18.54%
Return 5Y-94.59%

Ownership

Insiders Held14.47%
Institutions Held67.84%
Institutions Float Held79.32%
Institutional HolderSharesReport Date
Redmile Group, LLC15,470,5022026-03-31
TCG Crossover Management, LLC11,390,1752026-03-31
Prosight Management, Lp8,300,0002026-03-31
Blackrock Inc.6,250,7472026-03-31
Eventide Asset Management LLC5,701,6552026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ALMSAlumis Inc. $7.16 +2.73% -1.80 $883.77M 0.00%
AUTLAutolus Therapeutics plc $1.46 -13.61% -1.35 — 0.00%
BCYCBicycle Therapeutics plc $4.22 +0.24% -1.34 $292.84M 0.00%
FDMT4D Molecular Therapeutics, Inc. $13.33 +4.96% -5.03 $696.84M 0.00%
LCTXLineage Cell Therapeutics, Inc. $0.99 -3.50% -6.61 $247.80M 0.00%

About ADC Therapeutics SA

ADC Therapeutics SA is led by CEO Ameet Mallik, employs 263 people, headquartered in CH, publicly traded since 2020.

ADC Therapeutics SA (ADCT) stock trades at $1.73 with a market capitalization of $220.04M. The stock is valued at a price-to-earnings (P/E) ratio of -2.14, price-to-book of -0.96, price-to-sales of 2.29. Over the past 52 weeks the stock has ranged between $0.78 and $4.98, and currently trades 65.3% below its 52-week high.

On profitability, ADC Therapeutics SA generates a return on equity (ROE) of 44.63% — well above the market average, a sign of a high-quality business, return on capital employed of -51.34%, an operating margin of -133.33%, a net profit margin of -123.03%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNYSE High ROE StocksAll stock screens
Run Stock Screener Investing Guides